ChemoCentryx to Participate in Two Upcoming Investor Conferences
- 39th Annual
J.P. Morgan Healthcare Conference Wednesday, January 13at 11:40 a.m. Eastern Time H.C. Wainwright Virtual BioConnect Conference
On-demand presentation available beginning
Monday, January 11at 6:00 a.m. Eastern Time
- Clinical Trial Panel Discussion at the
H.C. Wainwright Virtual BioConnect Conference Monday, January 11at 12:00 p.m. Eastern Time
Live audio webcasts of the J.P. Morgan presentation and
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S.
ChemoCentryx also has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
Executive Vice President,
Chief Financial and Administrative Officer
Source: ChemoCentryx, Inc.